Literature DB >> 814637

Modified and unmodified umbilical vein allografts and xenografts as arterial substitutes: morphologic assessment.

H Dardik, I M Ibrahim, I Dardik.   

Abstract

Mesh:

Substances:

Year:  1975        PMID: 814637

Source DB:  PubMed          Journal:  Surg Forum        ISSN: 0071-8041


× No keyword cloud information.
  8 in total

1.  FEMORAL POPLITEAL BYPASS EMPLOYING MODIFIED HUMAN UMBILICAL CORD VEIN: AN ASSESSMENT OF EARLY CLINICAL RESULTS.

Authors:  Irving Dardik; Ibrahim Ibrahim; Herbert Dardik
Journal:  Cardiovasc Dis       Date:  1976

Review 2.  Factors contributing to success and failure of femorotibial bypass grafts.

Authors:  D F Courtney; W R Flinn; W J McCarthy; J S Yao; J J Bergan
Journal:  World J Surg       Date:  1988-12       Impact factor: 3.352

3.  Umbilical vein grafts.

Authors:  H Dardik
Journal:  Ann Surg       Date:  1978-04       Impact factor: 12.969

4.  The use of stabilized human umbilical vein for femoropopliteal bypass. Experience with 133 operations with 5-year follow-up.

Authors:  S A Hirsch; F Jarrett
Journal:  Ann Surg       Date:  1984-08       Impact factor: 12.969

5.  Preparation of venous allografts. A comparison of techniques.

Authors:  S C Balderman; M Montes; K Schwartz; T Hart; J N Bhayana; A A Gage
Journal:  Ann Surg       Date:  1984-08       Impact factor: 12.969

6.  Biodegradation and aneurysm formation in umbilical vein grafts. Observations and a realistic strategy.

Authors:  H Dardik; I M Ibrahim; B Sussman; M Kahn; M Sanchez; S Klausner; R E Baier; A E Meyer; I I Dardik
Journal:  Ann Surg       Date:  1984-01       Impact factor: 12.969

7.  Modification and morphology of human umbilical cord vein as canine arterial bypass grafts.

Authors:  K Esato; K Shintani; S Yasutake
Journal:  Ann Surg       Date:  1980-04       Impact factor: 12.969

8.  Human umbilical veins and autogenous veins as canine arterial bypass grafts.

Authors:  R W Oblath; F O Buckley; W A Donnelly; R M Green; J A Deweese
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.